Nervous Disorder TRIZ Cases

N6-(2-hydroxyethyl)-adenosine resolves metabolic instability and limited selectivity of existing agonists.

Human albumin mediates plasma exchange to increase hippocampal volume and improve cognitive symptoms without relying on amyloid-beta reduction.

Human facilitating cells induce donor-specific tolerance and durable chimerism, reducing graft-versus-host disease risk without harsh conditioning regimens.

A p75NTR NBP-Fc fusion protein combines a neurotrophin binding domain with an Fc portion to enhance molecular stability and therapeutic efficacy.

Ecklonia cava extracts replace viral vectors to dedifferentiate mesenchymal stem cells, resolving safety and efficiency bottlenecks.

Microwave irradiation of substituted 6-allyloxy-indanes in polar solvents retains stereochemistry and eliminates inert atmosphere requirements.

Engineered nanobodies penetrate the blood-brain barrier to inhibit complement system proteins.

WDFY3 gene variants boost Alfy expression, accelerating aggregate turnover and delaying disease onset.

Bifidobacterium breve MCC1274 extends non-REM and REM sleep duration, resolving inconsistent probiotic effects through strain-specific gut-brain axis mediation.

Antisense oligonucleotides reduce C9ORF72 transcript levels, addressing the limited treatment options for ALS and FTD patients.

Adeno-associated viral vector delivers frataxin polynucleotide to central nervous system cells for protein production.

Fucoidan ligands replace complex antibodies, reducing manufacturing costs while maintaining high selectin detection specificity.

Genetically engineered Yarrowia lipolytica cells produce homogeneous Man5GlcNAc2 glycoproteins through targeted gene deletions and enzyme modifications.

AAV9 vectors with CAG promoters restore enzyme activity, eradicating intracytoplasmic inclusions that current therapies fail to eliminate.

Combines ketamine with retigabine to reduce dissociative side effects while extending antidepressant response duration in treatment-resistant depression.

Segmented sodium nitrite dosing mitigates pain during initial phases while restoring nitric oxide bioavailability for microvascular treatment.

Anti-FAM19A5 antibodies increase mechanical and thermal stimulus thresholds while enhancing sensory nerve conduction velocity.

Extramuscular neurotoxin injection minimizes muscle weakness by targeting trigeminal cervical nerves through aponeurotic fascia diffusion.

Antioxidants protect nepetalactone from oxidation by fatty acids, maintaining chemical stability and diffusion effectiveness.

SUR1 and TRPM4 antagonists inhibit the NC Ca-ATP channel, reducing lesion volume and cell death in infants with intraventricular hemorrhage.

Dolichos lablab Linn. extract activates aldehyde dehydrogenase to degrade acetaldehyde, protecting the gastrointestinal wall from alcohol-induced damage.

Anti-mGluR2 nanobodies cross the blood-brain barrier to deliver therapeutic agents, bypassing invasive physical methods.

A pharmaceutical composition combining pyridoxamine and thiamine compounds to suppress advanced glycation end products.

Specific amine-based compounds inhibit Matriptase 2 activity, addressing the lack of effective modulators for iron-refractory iron deficiency anemia treatment.

Peptoids bind disease-specific antibodies to resolve diagnostic accuracy versus process complexity contradictions.

A pharmaceutical composition combining resveratrol, quercetin, and curcumin inhibits superactivated platelet aggregation.

IGF-2 receptor agonist ligands activate signaling pathways to reverse cognitive and motor deficits in Angelman Syndrome models.

Antibodies cross the blood-brain barrier to target and dissipate alpha-synuclein aggregates, addressing neurodegeneration where prior therapies failed.

Stable GCase chaperones restore brain enzyme activity by protecting protein folding, bypassing blood-brain barrier limits.

Lipid conjugation via cysteine residues enables FcRn-mediated recycling, extending half-life to reduce dosing frequency and serum fluctuation side effects.

Lonicera caerulea fruit extract reduces infarct volume and neurobehavioral impairments by protecting nerve cells against ischemic cerebrovascular damage.

Aticaprant targets kappa opioid receptors to treat depression while minimizing weight gain and sexual dysfunction side effects.

Segmented dosage stages resolve the trade-off between rapid sleep onset and sustained maintenance while minimizing side effects.

Modified pyrrolidine-benzoyl compounds overcome limited blood-brain barrier penetration and low affinity in current prolyl oligopeptidase inhibitors.

Prophylactic VPAC2 agonist administration enhances stress resilience and reduces anxiety-like behaviors in animal models.

Synthesizing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine via segmented amide and amino alcohol pathways.

A composition combining alpha-lipoic acid and carnosine treats phantom limb syndrome by reducing pain and sensation through antioxidant and anti-glycan mechanisms.

EZH2 inhibitors reduce H3-K27 methylation levels by targeting mutant protein forms, addressing insufficient treatment effectiveness in lymphoma patients.

A buprenorphine suspension in water with polyethylene glycol polymer delivers extended drug release profiles.

Once-daily guanfacine composition uses specific excipients to maintain linear pharmacokinetic profiles, reducing missed doses and improving patient compliance.

Pyrrolidine compounds act as agonists at human orexin receptors, addressing the lack of effective modulators for psychiatric conditions.

Panax quinquefolius gum attenuates cannabis dysphoria via falcarinol inverse agonism, resolving high-dose anxiety without compromising psychoactive effects.

Ginkgo biloba extracts complexed with phosphatidylserine enhance bioavailability of active ingredients.

Combining SV2A inhibitors with valproate addresses inadequate current therapies by slowing cognitive decline progression in CNS disorders.

Liver X receptor agonists improve hepatic function without altering copper levels, bypassing side effects of chelation therapy.

Bacterial vesicles from Lactobacillus paracasei activate AMPK signaling in myocytes to reduce body weight.

Post-translational modifications increase peptide stability and HSC70 affinity, addressing rapid elimination in autoimmune disease treatment.